Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 added to standard therapy in adults with active lupus nephritis
CTR20223376Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Iptacopan in lupus nephritis (LN) (3 arms), sponsored by Novartis. Primary endpoint: Proportion of patients achieving complete renal response without renal flare. Started Aug 2023; status: terminated.
02
Drugs
Iptacopan
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20223376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223376.